Fulcrum reports positive Phase 1b data for FTX-6058 in sickle cell disease; HbF up 6.3%

Fulcrum Therapeutics, Inc.

FTX-6058 achieved up to 6.3% increase in fetal hemoglobin (HbF) over baseline in Phase 1b trial.
Three evaluable subjects all showed HbF increases by day 28; maximal levels may not yet be reached.
FTX-6058 was generally well-tolerated; no serious TEAEs or discontinuations due to TEAEs.
Company plans to complete enrollment in current and two additional dose cohorts by end of 2022, with registrational trial start in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.